|
|
The Overlooked 3M Spinoff Just Caught a Fresh Buy Rating |
|
|
UBS just flipped this company to Buy and lifted its target to $95, one week before the 3M spinoff reports Q2 earnings. The stock closed at a fresh 52-week high, and sell-side coverage on it is still thin. |
|
|
|
|
|
|
|
|
Solventum Corporation |
|
|
July 30 – Pre‑market
Ticker: SOLV | Sector: Healthcare | Market Cap: ~$15.04B |
|
|
|
|
30‑Second Take |
Why now? UBS just flipped Solventum from Neutral to Buy, lifting its price target to $95 from $78. |
That's a 22% jump off a single upgrade note, and it landed one week before Q2 earnings on August 5. |
The stock is pressing new highs, so treat this as a momentum entry rather than a bottom-fish. |
The turnaround thesis is finally showing up in the numbers, the portfolio has been simplified, and coverage is still thin. If management delivers a decent print, this rerating has room to run. |
|
|
Trade Setup |
Time frame: Swing to medium-term (4 to 12 weeks)
Edge type: Analyst revision plus turnaround setup ahead of a catalyst |
|
|
|
|
|
|
How often do you check your portfolio during the trading day? |
|
|
|
|
Snapshot Table |
Metric |
Value |
Current Stance |
Price |
$86.82 |
At a fresh 52-week high |
52‑week range |
$62.38 – $88.65 |
Trading at the top of the range |
Market Cap |
~$15.04 |
Mid-cap, under-followed |
P/E Ratio |
N/A (negative TTM EPS) |
Cheap on forward EBITDA vs. medtech peers |
Beta |
0.72 |
Lower volatility profile |
Avg Daily Volume |
~1.8M shares |
Steady — no blow-off volume |
Next Catalyst |
Q2 earnings, August 5 |
Six trading days out |
|
|
|
Chart |
|
|
1-Month Synopsis: Over the past four weeks, SOLV has ground steadily higher, closing July 29 at $88.55, a fresh 52-week high on roughly 1.8 million shares. The advance has been orderly rather than parabolic, with every pullback getting bought. |
That's the kind of tape you want ahead of a catalyst: strength without froth. |
The UBS upgrade on July 29 broke the silence, and there are now six trading days before Q2 numbers hit. |
|
|
Bull Case |
Core thesis: Solventum is the healthcare business 3M spun off in April 2024, and it immediately traded like an orphan. |
Old assets, tired growth, too much debt. That was the story, and for a while it was fair. |
But management has been busy. They've been actively streamlining the portfolio, and the work on simplifying the business has given the company real breathing room to invest in the core medtech and dental segments. |
Catalysts: The pieces are falling into place. |
UBS upgraded to Buy from Neutral on July 29, with the price target lifted to $95 from $78. Portfolio simplification is underway. Debt levels have been reduced meaningfully as the balance sheet gets cleaner. |
The Medical Surgical and Dental Solutions segments have been showing sequential improvement. And Q2 earnings on August 5 give management a clean stage to reset guidance higher. |
Here's what makes this different from every other turnaround story you've read this year. Analyst coverage on Solventum is thin. Institutional ownership is still catching up. This is not a name that shows up on CNBC every morning. |
When a firm like UBS moves off the sidelines, it tends to bring others with it. That's the flywheel you want to be in front of. |
Valuation upside: The UBS target of $95 implies roughly 7% upside from the $88.55 close, and that's off a single upgrade. If Q2 confirms the trajectory and other sell-side firms follow, that number moves higher. |
|
|
Bear Case |
Let's be honest about the risks. |
3M spinoffs have a rough history. The parent tends to strip out the good stuff before the split, leaving the new entity with mature product lines and lawsuit exposure. |
Solventum still carries some of that overhang, including potential PFAS-related liabilities inherited from 3M. If new claims surface, the stock takes a hit fast. |
Then there's the growth question. Medtech peers like Baxter and Becton Dickinson trade at reasonable multiples because they're growing. Solventum is still proving it can grow at all. |
If Q2 comes in flat or management guides Q3 lower, this becomes another value trap, and the UBS upgrade looks premature. |
A few more things to watch: |
Currency headwinds could pressure results given international exposure. Competitive pressure in dental from Envista and Dentsply is real. Interest expense on remaining debt still eats into free cash flow. Any hint of PFAS litigation escalation would sink sentiment fast. |
The setup is compelling, but this is not a buy-and-forget name. Size it appropriately and have a plan if the August 5 print disappoints. |
Key takeaway: Build a starter position ahead of the August 5 Q2 earnings report, with room to add on any pullback. The UBS upgrade is your leading indicator that the turnaround narrative is finally getting recognized. If earnings confirm the trajectory, the rerating has room to run toward that $95 target. |
|
|
Quick Checklist |
✅ Thesis still valid after today's close
✅ Volume confirms move above key consolidation range
✅ Q2 earnings date confirmed for August 5
✅ Watch for follow-on upgrades from other sell-side firms |
|
|
Deep‑Dive Links |
|
|
|
|
That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned! |
Best Regards,
—Noah Zelvis
Everyday Alpha |
0 التعليقات:
إرسال تعليق